TY - JOUR AU - Schmerling, Rafael Aron PY - 2014 TI - Toxicity of checkpoint inhibitors JF - Chinese Clinical Oncology; Vol 3, No 3 (September 01, 2014): Chinese Clinical Oncology (Systemic Treatment of Cutaneous and Mucosal Melanoma - Guest Editors: Sanjiv S. Agarwala, Jun Guo, Antonio C. Buzaid) 1 Y2 - 2014 KW - N2 - Immunologic checkpoint inhibitor is a new class of antineoplastic drugs which mechanism of action depends on the interaction with the immune system. The first in class was ipilimumab, anti-CTLA4, and soon the anti-PD1 (Programmed Death 1) and anti-PDL1 are expected to be available. Although the profile of adverse events is unique, they are predictable and, by complying with the guidelines available, the management of these drugs is safe in the great majority of patients. Here, it is provided a review of adverse events and their management. UR - https://cco.amegroups.org/article/view/4330